Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 843.00 |
| Open | 841.70 |
| Bid | 849.00 x 0 |
| Ask | 848.90 x 0 |
| Day's range | 841.40 - 850.60 |
| 52-week range | 604.40 - 864.40 |
| Volume | |
| Avg. volume | 1,539,910 |
| Market cap | 1.898T |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 36.63 |
| EPS (TTM) | 23.18 |
| Earnings date | 01 Feb 2023 |
| Forward dividend & yield | 11.15 (1.31%) |
| Ex-dividend date | 12 Aug 2022 |
| 1y target est | 867.86 |
- Motley Fool
3 Healthcare Stocks That Could Set You Up For Life
Until that day, companies in the healthcare sector that can stay ahead of the curve will continue to thrive. Although this market is competitive, the company made its name by targeting the life sciences industry. In other words, Veeva Systems is a specialist, not a generalist.
- Zacks
Prothena (PRTA) Earns Milestone Payment From Novo Nordisk
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
- Reuters
Drug maker Novo Nordisk invests $744 million to expand Danish plant
COPENHAGEN (Reuters) -Danish drug maker Novo Nordisk said on Tuesday it plans to invest 5.4 billion Danish crowns ($744 million) to expand its facilities in Bagsvaerd, Denmark. The world's biggest producer of diabetes drugs, Novo said the project is expected to be finalised in 2024 and create about 160 new jobs. The investment would add capacity in research and development for manufacturing of active pharmaceutical ingredients (API), the main biologically active components of medicines, to supply its global clinical trials.
